达雷妥尤单抗用于治疗异基因干细胞移植后的纯红细胞再生障碍。 - Suppr

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

作者信息

Rautenberg Christina, Kaivers Jennifer, Germing Ulrich, Haas Rainer, Ackerstaff Stefanie, Hoffmann Till, Kobbe Guido, Schroeder Thomas

机构信息

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.

Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.

出版信息

Bone Marrow Transplant. 2020 Jun;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4. Epub 2019 Sep 3.

DOI:10.1038/s41409-019-0664-4

PMID:31481799

Abstract

摘要

相似文献

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

Bone Marrow Transplant. 2020 Jun;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4. Epub 2019 Sep 3.

Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.

Blood Cells Mol Dis. 2021 May;88:102464. doi: 10.1016/j.bcmd.2020.102464. Epub 2020 Jul 2.

Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.

Bone Marrow Transplant. 2022 Feb;57(2):282-285. doi: 10.1038/s41409-021-01507-3. Epub 2021 Oct 28.

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.

N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.

Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC.

Bone Marrow Transplant. 2024 Jun;59(6):893-895. doi: 10.1038/s41409-024-02202-9. Epub 2024 Mar 9.

Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment.

Acta Haematol. 2021;144(6):683-687. doi: 10.1159/000515257. Epub 2021 Apr 22.

Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation.

Transfusion. 2005 Apr;45(4):643-5. doi: 10.1111/j.0041-1132.2005.00445.x.

Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.

Bone Marrow Transplant. 2022 May;57(5):830-833. doi: 10.1038/s41409-022-01590-0. Epub 2022 Feb 22.

Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.

Haematologica. 2005 Nov;90 Suppl:ECR33.

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.

Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7.

引用本文的文献

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Blood Cancer J. 2025 Jun 4;15(1):106. doi: 10.1038/s41408-025-01315-8.

Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.

Kidney Int Rep. 2024 Aug 26;9(11):3250-3264. doi: 10.1016/j.ekir.2024.08.020. eCollection 2024 Nov.

Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.

World J Clin Cases. 2024 Aug 26;12(24):5604-5612. doi: 10.12998/wjcc.v12.i24.5604.

Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review.

Front Oncol. 2024 Jul 2;14:1386670. doi: 10.3389/fonc.2024.1386670. eCollection 2024.

Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab.

J Hematol. 2023 Dec;12(6):277-282. doi: 10.14740/jh1195. Epub 2023 Dec 9.

Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Leuk Res Rep. 2022 Apr 13;17:100314. doi: 10.1016/j.lrr.2022.100314. eCollection 2022.

Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature.

Mol Cell Pediatr. 2021 Apr 29;8(1):5. doi: 10.1186/s40348-021-00114-y.

Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Bone Marrow Transplant. 2021 Apr;56(4):769-778. doi: 10.1038/s41409-020-01124-6. Epub 2020 Nov 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

作者信息

Rautenberg Christina, Kaivers Jennifer, Germing Ulrich, Haas Rainer, Ackerstaff Stefanie, Hoffmann Till, Kobbe Guido, Schroeder Thomas

机构信息

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.

Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.

出版信息

Bone Marrow Transplant. 2020 Jun;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4. Epub 2019 Sep 3.

DOI:10.1038/s41409-019-0664-4

PMID:31481799

Abstract

摘要

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献